CJC-1295

Teichman et al. (J. Clin. Endocrinol. Metab.): Single injection increases GH 2-10x for 6+ days and IGF-1 1.5-3x for 9-11 days in healthy adults. Well-tolerated at 30-60 µg/kg.

Ionescu & Bhatt (J. Clin. Endocrinol. Metab.): Demonstrates 7.5-fold increase in basal GH, 46% increase in mean GH, and 45% increase in IGF-1 while preserving natural pulsatile pattern.

Animal study shows CJC-1295 increases total pituitary RNA and GH mRNA, suggesting proliferation of somatotroph cells for sustained GH production.

Therapeutic peptides offer mechanistically diverse approaches to targeting fundamental hallmarks of aging, a 2026 review demonstrated. While FDA-approved agents show clinical potential, investigational peptides require rigorous validation through well-designed trials to establish long-term safety and efficacy.

A 2026 review found that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, though rigorous human safety data remain scarce. The study investigated the pharmacological mechanisms and regulatory status of various sports medicine peptides.

Limited clinical evidence supports the use of performance-enhancing peptides in sports despite their growing popularity, a 2026 review found. The research highlighted significant potential risks, including cardiovascular strain and insulin resistance, alongside major challenges in regulation and anti-doping detection.

Therapeutic peptides such as BPC-157 and TB-500 were found to modulate key molecular pathways influencing tissue regeneration and inflammation resolution in a 2026 review. The study demonstrated that while preclinical mechanistic data is promising for orthopaedic applications, clinical trials remain lacking.

A 2026 review found a significant lack of human clinical evidence to support the use of peptides like BPC-157 and TB-4 in orthopaedics, despite demonstrating potential tissue repair benefits in preclinical models.

A 2026 study demonstrated the successful development and validation of a highly sensitive mass spectrometry method for detecting growth hormone-releasing hormone (GHRH) and its analogs, including sermorelin, tesamorelin, and CJC-1295, in urine. The method achieved limits of detection suitable for anti-doping screening.

A 2024 study demonstrated the successful development and validation of a simplified chromatographic-mass spectrometric method for detecting prohibited peptides, including insulins, GHRHs, and IGFs, in doping control urine samples. The approach met World Anti-Doping Agency standards and was verified using authentic post-administration samples.